Anastrazole
Sponsors
AstraZeneca, Mayo Clinic, University of Kansas Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Centre for Endocrinology and Reproductive Medicine, Italy
Conditions
Advanced Breast CancerAgingBreast CancerDuctal Carcinoma in SituEndometriosisHypogonadismInsulin ResistanceInvasive Breast Cancer
Phase 1
Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men
CompletedNCT00309855
Start: 2005-12-31End: 2008-08-31Updated: 2012-07-31
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
WithdrawnNCT04316169
Start: 2021-10-21End: 2028-01-31Updated: 2022-12-23
Phase 2
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
CompletedNCT00255463
Start: 2004-01-31End: 2005-11-30Target: 185Updated: 2009-04-23
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
CompletedNCT00259090
Start: 2004-04-30End: 2008-10-31Updated: 2012-08-16
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
CompletedNCT00921115
Start: 2009-05-31End: 2023-03-20Updated: 2023-05-19
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
RecruitingNCT06075953
Start: 2024-02-17End: 2033-11-01Target: 400Updated: 2026-03-16
Phase 4
Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
CompletedNCT01769781
Start: 2013-01-31End: 2015-07-31Updated: 2016-04-27
Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
CompletedNCT02959853
Start: 2016-06-30End: 2018-12-20Updated: 2020-01-30